Researchers from the Technical University of Munich presented study results at the American Urological Association's 2020 virtual meeting. A group led by Dr. Tobias Maurer found that F-18 PET/CT results using the compound, called rhPSMA-7.3, showed sensitivity of 81%, specificity of 88%, and diagnostic accuracy of 86% in 56 patients with intermediate or high-risk prostate cancer when compared with histopathological results.

These results have been included in Blue Earth's investigational new drug submission to the U.S. Food and Drug Administration.